The title of my book is Assessment of Hematological Parameters in Ischemic Stroke Patients. The study was done at hospital from January 2013 to July 2013. For this purpose samples were collected from local population and divided into two groups i.e. Ischemic and controlled. Data regarding risk factors was collected by Questionnaire. Their hematological parameters such as WBCs count, RBCs count, Hgb concentration, HCT, MCV, MCH and PLT count were assessed by hematology analyzer. Statistical analysis was done by using SPSS (Version 13). The WBCs count, MCV, MCH and HCT were found significantly higher in ischemic stroke subjects while significant decrease was observed in RBCs count and hemoglobin concentration. PLT count increased in ischemic stroke subjects. It is concluded that in ischemic stroke patients hematological parameters are greatly altered.
Cancer is one of the most dreaded diseases responsible for millions of deaths every year. In the present study, 12 medicinal plants from Jammu region, viz., Alstonia scholaris (devil tree), Azadirachta indica (neem), Calotropis gigantea (milk weed), Emblica officinalis (amla), Mentha citrata (bergamot mint), Mentha piperita (piper mint), Mentha viridis (pudina), Murraya koengii (kari pata), Musa paradisiaca (banana), Olea europaea (olive), Punica garanatum (pomegranate) and Trachyspermum ammi (ajwain) were evaluated against five human cancer cell lines from four different origins, viz., A-549 (lung), HCT-116 (colon), MCF-7 (breast), PC-3 (prostate) and T-47D (breast). 7 medicinal plants showed in vitro cytotoxic effect against one or the other human cancer cell line with the remarkable results produced by Calotropis gigantea (73-78% growth inhibition at 10 mig/ml against lung, colon and prostate cancer cells).To conclude, the plant can provide a great service and promise to cancer patients.
Diabetes mellitus is a metabolic affliction saunter that is characterized by a nobler than normal blood glucose poise. Glucose-6-phosphate dehydrogenase (G6PD) enzyme code (E.C.188.8.131.52) is an underlying enzyme in the phosphogluconate pathway. In this study, G6PD vitality in the mortal erythrocyte of male and female patients with type 2 diabetes mellitus was assessed utilizing a spectrophotometer at 340 nm. The activity of the enzyme increased with elevated glycated hemoglobin (HbA1C) levels. G6PD activity was found to be significantly associated with type 2 diabetes mellitus. The association between G6PD and diabetes mellitus was significant (P 0.001). Moreover, G6PD was positively correlated with HbA1C levels (r = 0.572). The following mean ± standard deviation values were obtained: G6PD activity (IU/g Hb), 3.1103 ± 0.79349, HbA1C (%), 8.6600 ± 1.63120, Hb (g/dL), 13.4933 ± 1.38836, platelet count (103/mil), 283.4667 ± 58.59312, WBC (103/mil), 7.4890 ± 1.49842, HCT (%), 45.0100 ± 2.63430, and BS (mg/dL), 230.2667 ± 75.67760. The results showed that an elevated HbA1C up leads to increased G6PD performance in the human erythrocyte, which is concerning to glucose levels.
Worldwide, a number of research groups are functioning towards effective treatment of colon cancer using chemotherapeutic agents. Nonsteroidal anti-inflammatory drugs are among the most potent agents discovered for the inhibition of cancer. In spite of the approval of celecoxib for adjuvant therapy in patients with familial adenomatous polyposis and precancerous disease of colon, associations of larger intensity of side effects limit its usage in cancer therapy. Combination therapy provides advantages of reduction in dose and possible reduction in toxicity and acquired drug resistance. As a consequence, targeted drug delivery and targeted molecular therapy of single or combination of anticancer agents are necessary for efficient treatment of colon cancer with reduced toxicity. In our study, combination of celecoxib and AEE788 shows growth inhibition and apoptosis in HCT 15 cells. Further, nanocarrier mediated celecoxib delivery showed high entrapment efficiency, sustained release patterns, desirable hemocompatibility and enhanced cytotoxicity and apoptosis in vitro and in vivo.
Recombinant technology has crucial impact in therapy development. In microbial environment, Pathogenic bacteria such as Staphylococcus aureus produces alpha hemolysin protein. This protein is used as anticancer protein. alpha hemolysin gene was isolated from pathogenic S. aureus that was isolated from blood samples of patients (chrildren). This recombinant hia gene was produced alpha hemolysin protein by using competent E. coli as a host. The recombinant - toxin protein was used as anticancer agent.In this study that high concentration of -toxin (500 mil/ ml) was effected on the cell viability of four cells line ( HepG-2, HCT-116, MCF-7, A-549). The cell viability of cell lines were represented 31.69% in HepG-2, 36.27% in HCT-116, 78.95% in MCF-7, 67.28% in A-549. From our results, Alpha hemolysin protein had high inhibitory activity against HepG-2 and HCT-116, and had weak inhibitory activity against MCF-7 and A-549. Inconclusion,The production of recombinant - toxin was very simple process, low cost, high efficiency, non-toxic, high yield and no side effect.
This comprehensive book thoroughly addresses all aspects of health care transition of adolescents and young adults with chronic illness or disability, and includes the framework, tools and case-based examples needed to develop and evaluate a Health Care Transition (HCT) planning program that can be implemented regardless of a patient's disease or disability. Health Care Transition: Building a Program for Adolescents and Young Adults with Chronic Illness and Disability is a uniquely inclusive resource, incorporating youth/young adult, caregiver, and pediatric and adult provider voices and perspectives. Part I of the book opens by defining Health Care Transition, describing the urgent need for comprehensive transition planning, barriers to HCT and then offering a framework for developing and evaluating health care transition programs. Part II focuses on the anatomic and neuro-chemical changes that occur in the brain during adolescence and young adulthood, and how they affect function and behavior. Part III covers the perspectives of important participants in the HCT transition process - youth and young adults, caregivers, and both pediatric and adult providers. Each chapter in Part IV addresses a unique aspect of developing HCT programs. Part V explores various examples of successful transition from the perspective of five key participants in the transition process - patients, caregivers, pediatric providers, adult providers and third party payers. Related financial matters are covered in part VI, while Part VII explores special issues such as HCT and the medical home, international perspectives, and potential legal issues. Models of HCT programs are presented in Part VIII, utilizing an example case study. Representing perspectives from over 75 authors and more than 100 medical centers in North America and Europe, Health Care Transition: Building a Program for Adolescents and Young Adults with Chronic Illness and Disability is an ideal resource for any clinician, policy maker, caregiver, or hospitalist working with youth in transition.
GVHD is a frequent complication of bone marrow transplant, with a high morbidity attributable to oral lesions that must be differentiated from other infections and autoimmune conditions occurring in oral mucosa. Interaction between hemato oncology and stomatology is needed for timely diagnosis and treatment of oral complications, and preventive intervention programs. Patients with history of oral cGVHD are at risk for number of late complications. In conclusion, oral cGVHD is a frequent and potential serious complication after allogenic HCT.